在持续的阿片类药物危机中，FDA 因批准阿片类药物成瘾风险基因测试 AvertD 而受到批评。 The FDA faces criticism for approving AvertD, a genetic test for opioid addiction risk, amid the ongoing opioid crisis.
美国食品药品监督管理局 (FDA) 因批准阿片类药物成瘾风险基因测试 AvertD 而面临强烈反对。 The FDA is facing backlash for approving AvertD, a genetic test for opioid addiction risk. 批评人士认为，该测试通过检测特定的基因标记来评估阿片类药物使用障碍的风险，过于简单化了成瘾风险，并可能对阿片类药物的处方实践产生重大影响。 Critics argue that the test, which detects specific genetic markers to assess the risk of opioid use disorder, oversimplifies addiction risk and may have a significant impact on opioid prescribing practices. 美国的阿片类药物危机在过去二十年中导致近 645,000 人死亡，2022 年据报道约有 610 万人患有阿片类药物使用障碍。 The opioid crisis in the US has resulted in nearly 645,000 deaths over the last two decades, and in 2022, approximately 6.1 million people were reported to have an opioid use disorder.